top of page

Watch "Deciphering Genetics & Genomics in Neuroendocrine Cancers">>

Home
About
Learn
Advocate
Connect
Resources
More

Use tab to navigate through the menu items.

G3 Neuroendocrine Neoplasms (NEN) or High Grade

G3 Neuroendocrine Neoplasms (NEN) or High Grade

Grade 3 NET

Alpha PRRT with Pb-212 VMT
CHM-2101 CAR-T cell for GI Cancers
COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETS
ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs
IL13Rα2 CAR T Cell Study for Solid Tumor Cancers
Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC
Lu-177 DOTATATE + Olaparib in GEP-NETs SORENTO™: Subcutaneous Octreotide for GEP-NETs (Cam2029)
SWOG S2104: Adjuvant CAPTEM for High Risk pNET

Neuroendocrine Carcinoma (NEC)

Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC
Alpha PRRT with Pb-212 VMT
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers
DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC)
IL13Rα2 CAR T Cell Study for Solid Tumor Cancers
Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC
Lu-177 DOTATATE + Sunitinib in PNETs
SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum
Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC

LACNETS
PO BOX 370466
DENVER, CO 80237

info@lacnets.org

TERMS & CONDITIONS

© 2024 by LACNETS

bottom of page